Hematologic Malignancies Articles

FDA Approves Carfilzomib Label Update in Myeloma
The FDA has approved a supplemental new drug application that adds overall survival data from the phase III ENDEAVOR trial to the label for carfilzomib for use in patients with relapsed or refractory multiple myeloma.
Emerging Therapies Generate Excitement in Myeloma
Thomas G. Martin, MD, discusses emerging advancements in the treatment landscape of multiple myeloma.
FDA Grants Tisagenlecleucel Priority Review for DLBCL
The FDA has granted a priority review to the CAR T-cell therapy tisagenlecleucel for adult patients with relapsed/refractory DLBCL who are ineligible for or relapse after autologous stem cell transplant. 
FDA Approves Arsenic Trioxide for Promyelocytic Leukemia
The FDA has approved arsenic trioxide (Trisenox) in combination with the all-trans retinoic acid agent tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia with the t(15;17) translocation or PML-RARA gene expression.
Axi-Cel Plus Atezolizumab Active, Safe in DLBCL
The combination of the CAR T-cell therapy axicabtagene ciloleucel and the PD-L1 inhibitor atezolizumab was highly active with a manageable safety profile in patients with refractory DLBCL enrolled in the phase I/II ZUMA-6 trial.
Expert Highlights RESPONSE Results With Ruxolitinib in Polycythemia Vera
Ruben A. Mesa, MD, discusses the significance of the RESPONSE study for patients with polycythemia vera.
Frontline Lenalidomide/Rituximab Combo Warrants Further Investigation in MCL
Jia Ruan, MD, PhD, discusses the pivotal analysis of the combination of lenalidomide plus rituximab, as well as the next steps for this regimen in the field of mantle cell lymphoma.
Combination Therapies Poised to Improve CLL Treatment Landscape
Aaron Logan, MD, PhD, discusses the most promising combinations and available treatments for patients with chronic lymphocytic leukemia.
FDA Approves Denosumab for Multiple Myeloma
The FDA has approved denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.
Interferon Continues to Show Promise as Myelofibrosis Option
Patients with myeloproliferative neoplasm‒associated myelofibrosis had prolonged treatment duration and improved survival compared with historical controls when treated with pegylated interferon alfa-2a.
Publication Bottom Border
Border Publication